Top Markets
#1 QuantixAI QuantixAI +102.83%
#2 MetaDAO MetaDAO +25.95%
#3 Pons Pons +24.24%
#4 龙虾 (Lobster) 龙虾 (Lobster) +24.22%
#5 DOG•GO•TO•THE•MOON (Runes) DOG•GO•TO•THE•MOON (Runes) +23.90%
#6 Rain Rain +21.62%
#7 Bedrock Bedrock +21.46%
#8 Ontology Gas Ontology Gas +20.44%
#9 SPX6900 SPX6900 +18.54%
#10 Prom Prom +17.73%
Coin of the day
QuantixAI QuantixAI
Configurações
Idioma
PORTUGUêS
Moeda
USD
Tema
Grifols, S.A. Grifols, S.A.

Grifols, S.A.

GRF
Classificação em ações #2537
Grifols, S.A., a Spanish company established in 1940 and headquartered in... Grifols, S.A., a Spanish company established in 1940 and headquartered in Barcelona, specializes in the comprehensive process of acquiring, manufacturing, preparing, and distributing therapeutic products, with a primary focus on those derived from plasma. The company operates through several key divisions: Bioscience, Hospital, Diagnostic, and Bio Supplies, among others. The Bioscience division is dedicated to the research, development, production, and commercialization of plasma-derived medicines and other cutting-edge solutions. These are designed to treat individuals suffering from chronic, rare, widespread, and life-threatening medical conditions, with its product portfolio including immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division supplies a range of non-biological pharmaceutical products, clinical nutrition items, intravenous (IV) therapy solutions, and various medical devices and supplies. Grifols' Diagnostic division develops and markets advanced diagnostic tools that support healthcare professionals across the entire patient care continuum, from prevention and screening to accurate diagnosis, prognosis, and ongoing disease and treatment monitoring. Finally, the Bio Supplies division provides essential biological materials for life-science research, clinical trials, and the manufacturing of both pharmaceutical and diagnostic goods. Collectively, Grifols' offerings enable healthcare providers to effectively diagnose and treat a broad spectrum of medical conditions, such as hemophilia, various immune deficiencies, and infectious diseases. Its diverse client base includes public and private sector organizations, wholesalers, distributors, group purchasing organizations (GPOs), blood banks, hospitals, care institutions, and national health systems. Grifols also maintains a technology collaboration agreement with Mondragon.
Preço da ação
$11.91
Valor de mercado
$8.11B
Variação (1 dia)
1.67%
Variação (1 ano)
-16.23%
País
ES
Negociar Grifols, S.A. (GRF)

Categoria

Healthcare
Rácio P/E de Grifols, S.A. (GRF)
Rácio P/E em 2026 TTM: 0
De acordo com os últimos relatórios financeiros e o preço das ações da Grifols, S.A., o rácio P/E atual (TTM) é 0. No final de 2026, a empresa tinha um P/E de 0.
Histórico do rácio P/E da Grifols, S.A. de 2026 a 2026
Rácio P/E no final de cada ano
Ano Índice P/E Alterar
Não há dados suficientes para as datas fornecidas.
Rácio P/E para empresas semelhantes ou concorrentes
Empresa Rácio P/E Diferença do rácio P/E País
Eli Lilly and Company Eli Lilly and Company
Eli Lilly and Company
LLY.US
 39.54 -
US
Johnson & Johnson Johnson & Johnson
Johnson & Johnson
JNJ.US
 30.10 -
US
AbbVie Inc. AbbVie Inc.
AbbVie Inc.
ABBV.US
 70.28 -
US
Roche Holding AG Roche Holding AG
Roche Holding AG
RO.SW
 22.25 -
CH
Merck & Co., Inc. Merck & Co., Inc.
Merck & Co., Inc.
MRK.US
 107.81 -
US
Como interpretar um P/E Ratio?

O rácio Preço/Lucro (P/E) mede a relação entre o preço da ação de uma empresa e o lucro por ação.
Um P/E baixo mas positivo representa uma empresa com altos lucros face à sua valorização atual e pode estar subvalorizada. Um P/E negativo elevado (perto de 0) representa perdas significativas.

Empresas com P/E acima de 30 ou negativo são geralmente vistas como "ações de crescimento", significando que os investidores esperam crescimento ou rentabilidade futura.

Empresas com P/E positivo inferior a 10 são geralmente consideradas "ações de valor", ou seja, já são muito lucrativas mas com pouco potencial de crescimento.